Antisoma Plc has reported positive results from a Phase 2 trial of its cancer drug, ASA404, which is intended to treat non-small-cell lung cancer. Data from the trial will be disclosed at the World Lung Cancer Conference in Soeul, Korea on 5 September 2007.
Marks & Clerk is to absorb the Lloyd Wise Group in a merger scheduled for completion by the end of 2007. Both firms are patent and trade mark attorneys based in London.
Vivalis, a French company that has developed a stem cell technology for the manufacture of vaccines, said it has licensed-in platform technology from North Carolina State University for producing undifferentiated avian cell cultures using avian primordial germ cells.
A proposed reform of US patent law, which is now before the US Congress, could have a significant impact on European life science companies doing business in the US as well as on efforts towards international patent harmonisation.
A team of international scientists using data collected from HIV-infected patients in Europe and Australia has identified three polymorphisms that appear to play a role in helping some of these individuals fight infection and delay the onset of AIDS.
TheraGenetics Ltd, a spinout from the Institute of Psychiatry at King's College in London in April 2006, hopes to have its gene-based diagnostic tests ready in about two years, its chief executive, Richard Kivel, said.
Novartis AG is seeking to get a decision by India’s Patent Office overturned by the country’s Intellectual Property Appellate Board (IPAB) despite losing a separate appeal in the High Court.
A new European guideline outlining how companies and regulators can identify and mitigate risks associated with the first studies in humans of novel medicinal products is due to take effect on 1 September 2007.
The UK government has decided to change its 50-year old system for indirectly setting the price of drugs sold to the National Health Service (NHS).
Shares of GPC Biotech AG have begun to recover after the company announced that it was withdrawing its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for accelerated approval of its cancer-drug candidate, satraplatin.